Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
(CYTH) $0.90 -Blockbuster in Phase 3 and has Alzheimer program in Phase 2b ...market cap only $9 million
DERM $1.50 has 9 marketed products and a phase 3 readout around the corner ..very cheap low floater here
presentation
https://d1io3yog0oux5.cloudfront.net/_b7a062e5f2348be102dfbd4056b8dfb2/journeymedicalcorp/db/2208/19996/pdf/Journey+Medical+Overview+FY+2022_.pdf
--
DERM $1.50 has 9 marketed products and a phase 3 readout expected during this quarter ..very cheap low floater here
presentation
https://d1io3yog0oux5.cloudfront.net/_b7a062e5f2348be102dfbd4056b8dfb2/journeymedicalcorp/db/2208/19996/pdf/Journey+Medical+Overview+FY+2022_.pdf
DERM $1.50 has 9 marketed products and a phase 3 readout around the corner ..very cheap low floater here
presentation
https://d1io3yog0oux5.cloudfront.net/_b7a062e5f2348be102dfbd4056b8dfb2/journeymedicalcorp/db/2208/19996/pdf/Journey+Medical+Overview+FY+2022_.pdf
(LCI) MC $18 m- Ph 3 data next week .. there is over 10% short interest on this low floater so any good news will send this stock skyrocketing
Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023
(LCI) MC $18 m- Ph 3 data next week .. there is over 10% short interest on this low floater so any good news will send this stock skyrocketing
Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023
(LCI) MC $18 m - Ph 3 data next week ...this low floater could double easily on positive outcome ..
Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023
(LCI) $2.04 -P3 data next week --Market Cap $21 million
Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023.....
$AYTU 3.30 low floater with many marketed drugs and near profitability ..market cap only $11 million
TALS $1.30 about to breakout , has massive $4.65 cash per share plus big drug in Phase 3
(CYTO) MC $6 m--Covid data in January.. this low floater could explode on positive results ..only 900k on the float
Database about to be locked in acute COVID-19 trial with Bentrio; top-line data expected by early January 2023
Strategic BentrioTM partnering or divestiture process enters decisive phase
Partnering or divestiture process for inner ear therapeutics assets ongoing
https://finance.yahoo.com/news/altamira-therapeutics-provides-end-2022-134700033.html
(AYTU) MC $12 m -Revenue $100+ m , has lots of marketed drugs + cash balance of $24 million -- Book Value of $17.20 per share and only 3.4 million outstanding shares
Presentation
https://cdn-dms-issuerservices.s3.amazonaws.com/9643/1004/1668797882/AYTU%20Corporate%20Presentation%20November%2015%202022%20FINAL.pdf
CYTH $2.10 next to explode ...market cap at laughable 18 million which has an big orphan drug in Phase 3 and Alzheimer treatment in Phase 2b its super cheap
(CYTH) $1.90 ..MC $17 mil -has Orphan drug in Phase 3 and Alzheimer treatment in Phase 2b ...likely the most attractive and underpriced biotech in the sector .
Pipeline
https://cyclotherapeutics.com/pipeline/
Presentation
https://s3.amazonaws.com/b2icontent.irpass.cc/2573/187895.pdf
ATXI up 59% to $2
ATXI $1.40 -MC $6 m -about to explodee , has a pain drug near FDA approval
(FBIO) $0.77 has 7x Phase 3 drugs and trading under cash + 8 Marketed Drugs and around 30 Drugs in early to mid stage ...Market cap $77 million while Cash balance is at $248 million...
Check out their presentation
https://d1io3yog0oux5.cloudfront.net/_5c15c03978b625f4b1541ea3d27ec409/fortressbiotech/db/640/5925/pdf/FBIO+Corporate+Presentation+-+Sept+2022.pdf
CYTO $5 -MC $6 m--Covid data readout THIS week.. this low floater could explode on positive results
Strategic BentrioTM partnering or divestiture process enters decisive phase
Partnering or divestiture process for inner ear therapeutics assets ongoing
Database about to be locked in acute COVID-19 trial with Bentrio; top-line data expected by early January 2023
https://finance.yahoo.com/news/altamira-therapeutics-provides-end-2022-134700033.html
(CYTH) MC $17 m -CHEAPEST Alzheimer stock on the entire US market . this low floater is unbelievable underpriced which has a big rare disease treatment in ongoing Phase 3 and Alzheimer drug in Phase 2b . If everything goes well this could be more than just a 10 bagger from current valuation of $17 million .
Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements
https://finance.yahoo.com/news/cyclo-therapeutics-provides-clinical-program-130500195.html
Pipeline
https://cyclotherapeutics.com/pipeline/
CYTO -MC $6 m--Covid data readout THIS week.. this low floater could explode on positive results
Database about to be locked in acute COVID-19 trial with Bentrio; top-line data expected by early January 2023
CYTO -MC $6 m--Covid data readout THIS week.. this low floater could explode on positive results
Strategic BentrioTM partnering or divestiture process enters decisive phase
Partnering or divestiture process for inner ear therapeutics assets ongoing
Database about to be locked in acute COVID-19 trial with Bentrio; top-line data expected by early January 2023
https://finance.yahoo.com/news/altamira-therapeutics-provides-end-2022-134700033.html
CYTO $5.40 -MC $6 m--Covid data readout THIS week.. this low floater could explode on positive results
Database about to be locked in acute COVID-19 trial with Bentrio; top-line data expected by early January 2023
Strategic BentrioTM partnering or divestiture process enters decisive phase
Partnering or divestiture process for inner ear therapeutics assets ongoing
https://finance.yahoo.com/news/altamira-therapeutics-provides-end-2022-134700033.html
CYTO $5.33 -MC $6 m--Covid data readout THIS week.. this low floater could explode on positive results
Strategic BentrioTM partnering or divestiture process enters decisive phase
Partnering or divestiture process for inner ear therapeutics assets ongoing
Database about to be locked in acute COVID-19 trial with Bentrio; top-line data expected by early January 2023
https://finance.yahoo.com/news/altamira-therapeutics-provides-end-2022-134700033.html
SNES $3 has only 670k shares out may benext HKD here
SNES $2.95 next HKD? only 670k O/S
CYTH now up 33% and still brutally underpriced at 18 million valuation
CYTH $1.60 -MC $16 m..Blockbuster in Phase 3 (NPC) and Phase 2 (Alzheimer)... one of the most underpriced low float biotech out there
https://cyclotherapeutics.com/pipeline/
CYTH up 23% next breakout opp
CYTH $1.50 -MC $15 m..Blockbuster in Phase 3 (NPC) and Phase 2 (Alzheimer)... one of the most underpriced low float biotech out there